GLP-1 agonists have become useful in many clinical conditions besides T2DM for which it was initially approved, including in patients with obesity (body mass index (BMI) of 30 and above) and patients with BMI of 27 and above with at least one weight-related complication [6]. Here, GLP1R is linked to obesity disorder.